CJC 1295 with Ipamorelin

$ 1,000

Type: Dual-peptide formulation
Composition:
- CJC-1295 (modified GHRH analog)
- Ipamorelin (see below)

Certificate of Analysis – CJC 1295 with Ipamorelin

What is CJC 1295 with Ipamorelin?

CJC-1295 with Ipamorelin is a combination of two potent growth hormone secretagogues frequently studied in the field of endocrinology and regenerative biology. CJC-1295 is a GHRH analog that stimulates growth hormone (GH) release over an extended period, while Ipamorelin is a selective ghrelin receptor agonist (GHRP) that triggers GH release in a pulsatile manner. Together, they provide a synergistic effect, promoting both the magnitude and frequency of GH secretion in research models.

Mechanism of Action

CJC-1295 operates by binding to the GHRH receptors in the pituitary gland, promoting the steady release of GH. Ipamorelin, on the other hand, mimics the action of ghrelin and binds to the growth hormone secretagogue receptor (GHSR), inducing rapid GH release without elevating prolactin or cortisol—an advantage over earlier GHRPs. When used together, CJC-1295 provides a sustained GH baseline while Ipamorelin promotes periodic GH spikes, creating a more natural and effective secretory pattern.

Solely for laboratory research purposes only. Not intended for human consumption.

Safety Profile

Preclinical and limited clinical studies suggest that both CJC-1295 and Ipamorelin have favorable safety profiles. Side effects noted in research contexts include mild headache, injection site irritation, and transient water retention. Importantly, Ipamorelin does not significantly affect appetite or stress hormone levels, making it well-tolerated in animal models.

Solely for laboratory research purposes only. Not intended for human consumption.

Key Studies

Clinical data from GHRH analog trials have shown increased serum IGF-1 levels and prolonged GH release following administration of CJC-1295.
Studies on Ipamorelin have demonstrated its efficacy in triggering GH release without undesired hormonal side effects, distinguishing it from older GHRPs like GHRP-6.
Combination studies suggest a synergistic effect on GH stimulation, muscle growth, and metabolic function.

Solely for laboratory research purposes only. Not intended for human consumption.

Conclusion

CJC-1295 with Ipamorelin is a powerful tool in the study of hormone regulation, aging, and tissue repair. Its dual-action mechanism provides a more complete model of GH secretion for researchers exploring long-term endocrine therapies, cellular growth, or regenerative processes. This combination is for research purposes only and is not intended for human consumption.

Solely for laboratory research purposes only. Not intended for human consumption.